Form 4: Emergent BioSolutions EVP, Chief Financial Officer Richard S. Lindahl Reports Changes in Beneficial Ownership

Richard S. Lindahl, EVP and CFO of Emergent BioSolutions Inc., reports adjustments in beneficial ownership due to performance stock unit vesting and tax withholdings.

Summary

• Richard S. Lindahl, the EVP and CFO of Emergent BioSolutions Inc., filed a Form 4 detailing changes in his beneficial ownership of the company's stock.
• On February 12, 2025, 16,916 performance stock units (PSUs) were disposed of because the achievement of the adjusted EBITDA margin target was not met, resulting in a payout factor of 0.00%.
• On February 28, 2025, 1,073 shares were disposed of to cover taxes related to the vesting and settlement of restricted stock units at a price of $7.48.
• On March 1, 2025, 683 shares were disposed of to cover taxes related to the vesting and settlement of restricted stock units at a price of $7.48.
• Following these transactions, Lindahl's direct ownership is 152,337 shares of common stock.
• The filing was submitted late due to an administrative error.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the failure to meet performance targets for PSU vesting and the late filing of the Form 4. However, the impact is limited to executive compensation and administrative matters.

Negatives

• The filing of Form 4 was late due to an inadvertent administrative error, which the company will address in its next proxy statement.
• Performance stock units did not vest due to the company not meeting the adjusted EBITDA margin target.

Risks

• Administrative errors in SEC filings could lead to regulatory scrutiny.
• Failure to meet performance targets can impact executive compensation and morale.

Management Comments

• The Company will report all late Form 4s in its next proxy statement.

Industry Context

Executive compensation and stock ownership are standard disclosures for publicly traded companies. The vesting of performance-based equity is tied to company performance, reflecting alignment of executive incentives with shareholder value.

Comparison to Industry Standards

• Emergent BioSolutions' use of performance-based equity compensation is a common practice among publicly traded companies to align executive incentives with shareholder value.
• Companies like Moderna, Pfizer, and Johnson & Johnson also utilize similar performance metrics, such as revenue growth, clinical trial milestones, and regulatory approvals, to determine executive compensation.
• The specific EBITDA margin target and payout structure would be benchmarked against peer companies in the biotechnology and pharmaceutical industries to ensure competitiveness and alignment with industry standards.

Stakeholder Impact

• Shareholders may be concerned about the company's ability to meet performance targets.
• Employees may be affected by changes in executive compensation structures.

Key Dates

Keywords

Emergent BioSolutions, Richard S. Lindahl, Form 4, beneficial ownership, performance stock units, PSUs, EBITDA margin, restricted stock units, tax withholding, SEC filing